Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference

Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347

Lausanne, Switzerland – April 16, 2015 – Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that preclinical data on the investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2015 Annual meeting of the American Association for Cancer Research (AACR) taking place in Philadelphia.

“Oncology has and will continue to benefit from combined and targeted therapies. Results from these preclinical studies underscore the potential clinical value of our two anti-cancer targeted therapies” said Dr Nigel McCracken, Vice President, Translational Medicine. “Currently both Debio 1143 and Debio 1347 are in Clinical Development and Debiopharm remains committed to exploring new combinations and new indications to provide improved benefit to patients suffering from cancers”.

AACR 2015 Abstract

<table>
<thead>
<tr>
<th>COMPOUND</th>
<th>TITLE</th>
<th>DATE AND TIME</th>
<th>N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debio 1143</td>
<td>SMAC mimetic and radiotherapy synergize to enhance antitumor immunity in lung cancer by targeting immunosuppressive cells</td>
<td>Sun, Apr 19, 1:00 - 5:00 pm</td>
<td>#283</td>
</tr>
<tr>
<td>Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma</td>
<td>Mon, Apr 20, 1:00 - 5:00 pm</td>
<td>#2529</td>
<td></td>
</tr>
<tr>
<td>The IAP inhibitor Debio 1143 reverses carboplatin resistance in ovarian cancer cells by inducing both apoptosis and necroptosis</td>
<td>Mon, Apr 20, 1:00 - 5:00 pm</td>
<td>#2700</td>
<td></td>
</tr>
<tr>
<td>Debio 1347</td>
<td>Characterization of two novel oncogenic FGFR2 fusions sensitive to the FGFR-selective inhibitor Debio 1347 in cholangiocarcinoma</td>
<td>Sun, Apr 19, 1:00 - 5:00 pm</td>
<td>#689</td>
</tr>
<tr>
<td>Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in-human dose escalation trial in solid tumors patients</td>
<td>Mon, April 20, 8:00 - 12:00 am</td>
<td>Abstract CT228</td>
<td></td>
</tr>
<tr>
<td>Additional poster regarding Debio 1347 to be presented by Chugai Pharmaceutical, the originator of the compound: Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1</td>
<td>Sun, Apr 19, 1:00 - 5:00 pm</td>
<td>Abstract #123</td>
<td></td>
</tr>
</tbody>
</table>
About Debiopharm International SA
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide. For more information, please visit: [www.debiopharm.com](http://www.debiopharm.com)
We are on Twitter. Follow us @DebiopharmNews at [http://twitter.com/DebiopharmNews](http://twitter.com/DebiopharmNews)

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel: +41 (0)21 321 01 11

Additional Media Contacts
In London
Maitland
Martin Barrows
mbarrow@maitland.co.uk
Tel: +44 (0)20 7395 0444

In New York
Russo Partners, LLC
Marissa Goberdhan
Account Executive
marissa.goberdhan@russopartnersllc.com
Tel: +1 212-845-4253